Privia (PRVA) Q3 2026 Earnings Call Transcript

Privia Health reported Q3 revenue of $657.0 million, up 13.2% year over year, and net income of $13.5 million, up 96.6%; adjusted EBITDA was $40.6 million, up 6.3%. The company raised its full-year 2026 outlook, forecasting revenue of $2.50 billion–$2.55 billion and adjusted EBITDA of $154 million–$157 million, with midpoint EBITDA growth of 23.9%. Privia also agreed to acquire American Choice Healthcare for approximately $36 million in cash, expected to add more than 36,000 attributed lives starting in 2027; its Montana partnership exit is expected to have no material impact on 2027 adjusted EBITDA.

Analysis

The key underwriting question is whether provider and attributed-life growth converts into durable care-margin dollars—not whether reported GAAP revenue accelerates. Florida’s move from administrative-services-only to full-GAAP recognition can lift revenue without equivalent economics; collections, care margin, and EBITDA are better quality checks. The gap between guided care-margin and EBITDA growth implies continued operating leverage, but it raises the bar for execution as the company approaches its stated margin range.

The American Choice deal adds lives, but attribution alone does not establish returns: verify the acquired ACO’s historical savings, benchmark exposure, retention, and integration costs before extrapolating accretion. CMS settlement timing also makes near-term cash conversion less informative; the lower 2026 conversion outlook versus recent realized rates is a working-capital/tax watch item, not yet evidence of deteriorating earnings quality.

Over 1–3 months, CMS MSSP results and the 10-Q are the cleanest tests of VBC performance and cash assumptions. Over 6–18 months, regulatory and attribution shifts could create acquisition supply and provider recruitment opportunities, while also disrupting contract economics. The Montana exit is a localized portfolio decision; management expects no material PRVA EBITDA effect, so it is not a basis to infer broad weakness at Surgery Partners (SGRY). Contrarian risk: investors may capitalize provider and lives growth too directly, overlooking revenue-mix effects and uncertain acquired-ACO economics.

Key Decisions for Investors

• PRVA: Prefer a staged long on post-results weakness rather than chasing the guidance raise. Reassess after the 10-Q and CMS MSSP results; the thesis is operating leverage plus organic provider growth, with upside contingent on care-margin growth translating to EBITDA and cash.
• Use care margin, adjusted EBITDA, and free-cash-flow conversion—not GAAP revenue alone—as confirmation. Falsify the thesis if subsequent results show care-margin growth lagging collections persistently, EBITDA conversion weakening beyond the stated 70%–75% long-run range without a timing explanation, or guidance being cut.
• Treat American Choice as a diligence catalyst, not a proven earnings driver. Seek acquired-ACO savings history, benchmark/settlement sensitivity, and provider retention; avoid valuing the added attributed lives as equivalent to established organic lives until disclosed.
• No trade in SGRY on the Montana exit alone: the stated PRVA impact is immaterial to EBITDA, and the transcript does not establish a broader change in SGRY economics.